Tustin, CA: The percentages of cannabinoids advertised on the labels of grey market delta-8 THC products is typically inaccurate, according to an analysis of products by an independent testing laboratory.
Of the 51 products analyzed, 77 percent possessed less delta-8 THC than advertised. Three-quarters of the products also contained higher levels of THC than permitted by federal law. Dozens of assessments of the potency and quality of unregulated, over-the-counter CBD products have revealed similar discrepancies.
Although delta-8 THC appears organically in cannabis, it is only produced in minute amounts. By contrast, the elevated quantities of delta-8 THC found in grey market products is the result of a chemical synthesis during which manufacturers convert CBD to delta-8 THC. Manufacturers engaged in synthetizing delta-8 THC are not regulated and may use potentially dangerous household products to facilitate this process.
Statements issued by the US Drug Enforcement Agency in the Federal Register in 2020 indicated that delta-8 THC products are federally illegal because they contain “synthetically derived” cannabinoids. The substance is also among those explicitly identified as a Schedule I drug by the DEA. In recent months, lawmakers in several states have also taken steps to prohibit the manufacture and sale of such products.
Last month, NORML issued a report on delta-8 THC and other novel, synthetically derived cannabinoids that cautioned consumers to avoid these unregulated products because they are untested and may contain impurities.
Full text of NORML’s report, “NORML’s Guide to Delta-8 THC and Other Novel Cannabinoids,” appears online.